Immuron Ltd Files 6-K for September 2024
Ticker: IMRN · Form: 6-K · Filed: Sep 5, 2024 · CIK: 1660046
| Field | Detail |
|---|---|
| Company | Immuron LTD (IMRN) |
| Form Type | 6-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Immuron Ltd filed a 6-K, standard update for foreign private issuers. No major news yet.
AI Summary
Immuron Limited filed a Form 6-K on September 5, 2024, reporting its activities for the month of September 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing serves as an update for investors regarding Immuron Ltd's regulatory compliance and reporting status as a foreign private issuer.
Risk Assessment
Risk Level: low — The filing is a routine administrative report and does not contain material non-public information that would typically impact risk.
Key Players & Entities
- Immuron Limited (company) — Registrant
- 001-38104 (company) — Commission File Number
- 20240905 (date) — Filing Date
- September 2024 (date) — Reporting Period
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, have filed or are required to file with a stock exchange, or have distributed or are required to distribute to their security holders.
What is Immuron Limited's commission file number?
Immuron Limited's commission file number is 001-38104.
What is Immuron Limited's principal executive office address?
Immuron Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Immuron Limited file annual reports under Form 20-F?
Yes, Immuron Limited indicates it files annual reports under cover of Form 20-F.
What period does this Form 6-K cover?
This Form 6-K covers the month of September 2024.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 18.6 · Accepted 2024-09-05 08:00:03
Filing Documents
- ea0213574-6k_immuron.htm (6-K) — 13KB
- ea021357401ex99-1_immuron.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 7KB
- ex99-1_003.jpg (GRAPHIC) — 3KB
- ex99-1_004.jpg (GRAPHIC) — 42KB
- 0001213900-24-075787.txt ( ) — 110KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on September 5, 2024 titled: - “Immuron Plans Phase 2 Trial for IMM-529 following FDA review” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Immuron Plans Phase 2 Trial for IMM-529 following FDA review 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: September 5, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3